Updating results

Suicide prevention: optimising medicines and reducing access to medicines as a means of suicide (KTT24)

KTT24 Suicide prevention: optimising medicines and reducing access to medicines as a means of suicide Key points

Key therapeutic topic Published March 2019 Last updated September 2019

Shared decision making (KTT23)

KTT23 Shared decision making Key points In the context of medicines optimisation, shared

Key therapeutic topic Published March 2019 Last updated September 2019

Chemotherapy dose standardisation (KTT22)

KTT22 Chemotherapy dose standardisation Key points Chemotherapy dose standardisation

Key therapeutic topic Published February 2018 Last updated September 2019

Type 2 diabetes mellitus: medicines optimisation priorities (KTT12)

KTT12 Type 2 diabetes mellitus: medicines optimisation priorities Key points The NICE

Key therapeutic topic Published January 2015 Last updated September 2019

Multimorbidity and polypharmacy (KTT18)

KTT18 Multimorbidity and polypharmacy Key points Multimorbidity is associated with

Key therapeutic topic Published January 2017 Last updated September 2019

Asthma: medicines safety priorities (KTT5)

KTT5 Asthma: medicines safety priorities Key points Inhaled corticosteroids (ICS) are

Key therapeutic topic Published January 2015 Last updated September 2019

Antimicrobial stewardship: prescribing antibiotics (KTT9)

KTT9 Antimicrobial stewardship: prescribing antibiotics Key points Antimicrobial resistance

Key therapeutic topic Published January 2015 Last updated September 2019

Medicines optimisation in chronic pain (KTT21)

KTT21 Medicines optimisation in chronic pain Key points Controlling chronic pain can

Key therapeutic topic Published January 2017 Last updated September 2019

Acute kidney injury (AKI): use of medicines in people with or at increased risk of AKI (KTT17)

KTT17 Acute kidney injury (AKI): use of medicines in people with or at increased risk of AKI Key points

Key therapeutic topic Published February 2016 Last updated September 2019

Hypnotics (KTT6)

KTT6 Hypnotics Key points The risks associated with hypnotics (including melatonin)

Key therapeutic topic Published January 2015 Last updated September 2019

Anticoagulants, including direct-acting oral anticoagulants (DOACs) (KTT16)

KTT16 Anticoagulants, including direct-acting oral anticoagulants (DOACs) Key points

Key therapeutic topic Published February 2016 Last updated September 2019

Lipid-modifying drugs (KTT3)

KTT3 Lipid-modifying drugs Key points The NICE guideline on cardiovascular disease:

Key therapeutic topic Published January 2015 Last updated September 2019

Antipsychotics in people living with dementia (KTT7)

KTT7 Antipsychotics in people living with dementia Key points The risks and limited

Key therapeutic topic Published January 2015 Last updated September 2019

Wound care products (KTT14)

KTT14 Wound care products Key points A large number of wound dressings are available

Key therapeutic topic Published January 2015 Last updated September 2019

Safer insulin prescribing (KTT20)

KTT20 Safer insulin prescribing Key points Several new insulin products have been launched

Key therapeutic topic Published January 2017 Last updated September 2019

Psychotropic medicines in people with learning disabilities whose behaviour challenges (KTT19)

KTT19 Psychotropic medicines in people with learning disabilities whose behaviour challenges Key points

Key therapeutic topic Published January 2017 Last updated September 2019

Doxylamine/pyridoxine (Xonvea) for treating nausea and vomiting of pregnancy (ES20)

Summary of the evidence on doxylamine/pyridoxine (Xonvea) for treating nausea and vomiting of pregnancy in women aged 18 years and older to inform local NHS

Evidence summary Published June 2019

Opioid dependence: buprenorphine prolonged-release injection (Buvidal) (ES19)

Summary of the evidence on buprenorphine prolonged-release subcutaneous injection (Buvidal) for opioid dependence to inform local NHS

Evidence summary Published February 2019

Chronic obstructive pulmonary disease: fluticasone furoate, umeclidinium and vilanterol (Trelegy) (ES18)

Summary of the evidence on fluticasone furoate, umeclidinium and vilanterol (Trelegy) for chronic obstructive pulmonary disease (COPD) to inform local NHS

Evidence summary Published June 2018

Chronic obstructive pulmonary disease: beclometasone, formoterol and glycopyrronium (Trimbow) (ES17)

Summary of the evidence on beclometasone, formoterol and glycopyrronium (Trimbow) for chronic obstructive pulmonary disease (COPD) to inform local NHS planning

Evidence summary Published May 2018

Biosimilar medicines (KTT15)

KTT15 Biosimilar medicines Options for local implementation Biosimilar medicines have

Key therapeutic topic Published February 2016 Last updated February 2018

Non-steroidal anti-inflammatory drugs (KTT13)

KTT13 Non-steroidal anti-inflammatory drugs Options for local implementation Review

Key therapeutic topic Published January 2015 Last updated February 2018

Antimicrobial prescribing: Ceftazidime/avibactam (ES16)

Summary of the evidence on ceftazidime/avibactam for complicated intra-abdominal and UTI infections and hospital-acquired pneumonia

Evidence summary: antimicrobial prescribing Published November 2017

Early breast cancer (preventing recurrence and improving survival): adjuvant bisphosphonates (ES15)

Summary of the evidence on adjuvant bisphosphonates for preventing recurrence or improving survival in people with early breast cancer

Evidence summary Published July 2017

Obese, overweight with risk factors: liraglutide (Saxenda) (ES14)

Summary of the evidence on liraglutide for managing obesity and overweight with risk factors in adults to inform local NHS planning and decision-making

Evidence summary Published June 2017

Preventing recurrence of Clostridium difficile infection: bezlotoxumab (ES13)

Summary of the evidence on bezlotoxumab for preventing the recurrence of Clostridium difficile (C difficile) infection

Evidence summary Published June 2017

Non-cystic fibrosis bronchiectasis: inhaled tobramycin (ES12)

ES12 Non-cystic fibrosis bronchiectasis: inhaled tobramycin Key points

Evidence summary Published April 2017

Mitochondrial disorders in children: Co-enzyme Q10 (ES11)

Summary of the evidence on co-enzyme Q10 for mitochondrial disorders in children to inform local NHS planning and decision-making

Evidence summary Published March 2017

Hyperhidrosis: oxybutynin (ES10)

Summary of the evidence on oxybutynin for treating hyperhidrosis (excessive sweating) to inform local NHS planning and decision-making

Evidence summary Published March 2017

Parkinson's disease with end-of-dose motor fluctuations: opicapone (ES9)

Summary of the evidence on opicapone for reducing end-of-dose motor fluctuations in Parkinson’s disease to inform local NHS planning and decision-making

Evidence summary Published March 2017

Narcolepsy with or without cataplexy in adults: pitolisant (ES8)

Summary on the evidence on pitolisant for treating narcolepsy with or without cataplexy to inform local NHS planning and decision-making

Evidence summary Published March 2017

Skin involvement in systemic sclerosis: rituximab (ES7)

Summary of the evidence on rituximab (MabThera) for treating skin involvement in systemic sclerosis to inform local NHS planning and decision-making

Evidence summary Published March 2017

Parkinson's disease with motor fluctuations: safinamide (ES6)

Summary of the evidence on safinamide for treating Parkinson’s disease with motor fluctuations to inform local NHS planning and decision-making

Evidence summary Published February 2017

Severe sialorrhoea (drooling) in children and young people with chronic neurological disorders: oral glycopyrronium bromide (ES5)

Summary of the evidence on oral glycopyrronium bromide for severe sialorrhoea (drooling) in children and young people with chronic neurological disorders

Evidence summary Published February 2017

Refractory extrapulmonary sarcoidosis: infliximab (ES4)

Summary of the evidence on infliximab for treating refractory extrapulmonary sarcoidosis to inform local NHS planning and decision-making

Evidence summary Published January 2017

Oestrogen deficiency symptoms in postmenopausal women: conjugated oestrogens and bazedoxifene acetate (ES3)

Summary of the evidence on conjugated oestrogens and bazedoxifene acetate for oestrogen deficiency symptoms to inform local NHS planning and decision-making

Evidence summary Published December 2016

Pulmonary sarcoidosis: infliximab (ES2)

Summary of the evidence on infliximab for treating pulmonary sarcoidosis to inform local NHS planning and decision-making

Evidence summary Published December 2016

Minimal change disease and focal segmental glomerulosclerosis in adults: rituximab (ES1)

Summary of the evidence on rituximab for minimal change disease and focal segmental glomerulosclerosis to inform local NHS planning and decision-making

Evidence summary Published November 2016

Pre-exposure prophylaxis of HIV in adults at high risk: Truvada (emtricitabine/tenofovir disoproxil) (ESNM78)

Summary of the evidence on Truvada (emtricitabine/tenofovir disoproxil) for pre-exposure prophylaxis (PrEP) of HIV in adults at high risk

Evidence summary Published October 2016

Moderate to severe acute post-operative pain: fentanyl transdermal system (ESNM77)

This evidence summary was withdrawn in September 2017 as the medicine is no longer available.

Evidence summary Published June 2016

Visual impairment due to myopic choroidal neovascularisation: aflibercept (ESNM76)

This evidence summary has been replaced by NICE technology appraisal guidance 486.  

Evidence summary Published June 2016

Complicated urinary tract infections: ceftolozane/tazobactam (ESNM74)

Summary of the evidence on ceftolozane/tazobactam for treating complicated urinary tract infections to inform local NHS planning and decision-making

Evidence summary Published June 2016

Complicated intra-abdominal infections: ceftolozane/tazobactam (ESNM75)

Summary of the evidence on ceftolozane/tazobactam for treating complicated intra-abdominal infections to inform local NHS planning and decision-making

Evidence summary Published June 2016

Reversal of the anticoagulant effect of dabigatran: idarucizumab (ESNM73)

Summary of the evidence on idarucizumab for reversing the anticoagulant effect of dabigtatran to inform local NHS planning and decision-making

Evidence summary Published May 2016

Chronic obstructive pulmonary disease: tiotropium/olodaterol (Spiolto Respimat) (ESNM72)

Summary of the evidence on tiotropium/olodaterol (Spiolto Respimat) for treating chronic obstructive pulmonary disease (COPD)..

Evidence summary Published May 2016

Moderate to severe acute post­-operative pain: sufentanil sublingual tablet system (ESNM71)

Summary of the evidence on the sufentanil sublingual tablet system for treating post­operative pain to inform local NHS planning and decision-making

Evidence summary Published March 2016

Chronic wounds: advanced wound dressings and antimicrobial dressings (ESMPB2)

Summary of the evidence on advanced wound dressings and antimicrobial dressings for managing chronic wounds to inform local NHS planning and decision-making

Evidence summary Published March 2016

Pulmonary hypertension in neonates: sildenafil (ESUOM51)

Summary of the evidence on sildenafil for treating pulmonary hypertension in neonates to inform local NHS planning and decision-making

Evidence summary Published March 2016

Attention deficit hyperactivity disorder in children and young people: guanfacine prolonged-release (ESNM70)

Summary of the evidence on guanfacine prolonged-release for attention deficit hyperactivity disorder (ADHD) to inform local NHS planning and decision-making

Evidence summary Published March 2016

Prevention of chemotherapy induced nausea and vomiting in adults: netupitant/palonosetron (ESNM69)

Summary of the evidence on netupitant/palonosetron to prevent chemotherapy induced nausea and vomiting to inform local NHS planning and decision-making

Evidence summary Published March 2016